These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32694037)

  • 1. Cognitive dysfunction in a psychotropic medication-naïve, clinical high-risk sample from the ShangHai-At-Risk-for-Psychosis (SHARP) study: Associations with clinical outcomes.
    Cui H; Giuliano AJ; Zhang T; Xu L; Wei Y; Tang Y; Qian Z; Stone LM; Li H; Whitfield-Gabrieli S; Niznikiewicz M; Keshavan MS; Shenton ME; Wang J; Stone WS
    Schizophr Res; 2020 Dec; 226():138-146. PubMed ID: 32694037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline.
    Carrión RE; Walder DJ; Auther AM; McLaughlin D; Zyla HO; Adelsheim S; Calkins R; Carter CS; McFarland B; Melton R; Niendam T; Ragland JD; Sale TG; Taylor SF; McFarlane WR; Cornblatt BA
    J Psychiatr Res; 2018 Jan; 96():231-238. PubMed ID: 29121595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive Assessments Are More Important Among Adolescents Than Adults for Predicting Psychosis in Clinical High Risk.
    Zhang T; Cui H; Wei Y; Tang X; Xu L; Hu Y; Tang Y; Chen T; Li C; Wang J
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2022 Jan; 7(1):56-65. PubMed ID: 34274517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study.
    Seidman LJ; Shapiro DI; Stone WS; Woodberry KA; Ronzio A; Cornblatt BA; Addington J; Bearden CE; Cadenhead KS; Cannon TD; Mathalon DH; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW
    JAMA Psychiatry; 2016 Dec; 73(12):1239-1248. PubMed ID: 27806157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis.
    Carrión RE; McLaughlin D; Auther AM; Olsen R; Correll CU; Cornblatt BA
    Psychol Med; 2015 Nov; 45(15):3341-54. PubMed ID: 26169626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive function as a possible marker for remission from clinical high risk for psychosis.
    Lee TY; Shin YS; Shin NY; Kim SN; Jang JH; Kang DH; Kwon JS
    Schizophr Res; 2014 Mar; 153(1-3):48-53. PubMed ID: 24529365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and to Be Most Promising for Predictive Algorithms for Conversion to Psychosis: A Meta-Analysis.
    Hauser M; Zhang JP; Sheridan EM; Burdick KE; Mogil R; Kane JM; Auther A; Carrión RE; Cornblatt BA; Correll CU
    J Clin Psychiatry; 2017 Jan; 78(1):e28-e40. PubMed ID: 28129494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.
    Velthorst E; Meyer EC; Giuliano AJ; Addington J; Cadenhead KS; Cannon TD; Cornblatt BA; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Bearden CE; Seidman LJ
    Schizophr Res; 2019 Feb; 204():311-319. PubMed ID: 30078717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts.
    Kennedy L; Ku BS; Addington J; Amir CM; Bearden CE; Cannon TD; Carrión R; Cornblatt B; Keshavan M; Perkins D; Mathalon D; Stone W; Walker E; Woods S; Cadenhead KS
    Schizophr Res; 2024 Sep; 271():319-331. PubMed ID: 39084107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of longitudinal neurocognitive performance in people at clinical high-risk for psychosis.
    Hedges EP; See C; Si S; McGuire P; Dickson H; Kempton MJ
    Psychol Med; 2022 Aug; 52(11):2009-2016. PubMed ID: 35821623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auditory N100 amplitude deficits predict conversion to psychosis in the North American Prodrome Longitudinal Study (NAPLS-2) cohort.
    Duncan E; Roach BJ; Massa N; Hamilton HK; Bachman PM; Belger A; Carrion RE; Johannesen JK; Light GA; Niznikiewicz MA; Addington JM; Bearden CE; Cadenhead KS; Cannon TD; Cornblatt BA; McGlashan TH; Perkins DO; Tsuang M; Walker EF; Woods SW; Nasiri N; Mathalon DH
    Schizophr Res; 2022 Oct; 248():89-97. PubMed ID: 35994912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Various neurocognitive deficits and conversion risk in individuals at clinical high risk for psychosis.
    Mourik K; Decrescenzo P; Brucato G; Gill KE; Arndt L; Kimhy D; Keilp JG; Girgis RR
    Early Interv Psychiatry; 2017 Jun; 11(3):250-254. PubMed ID: 26663764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive dysfunction in subjects at clinical high risk for psychosis: A meta-analysis.
    Zheng W; Zhang QE; Cai DB; Ng CH; Ungvari GS; Ning YP; Xiang YT
    J Psychiatr Res; 2018 Aug; 103():38-45. PubMed ID: 29772485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between age and neurocognition in individuals at clinical high risk and first-episode psychosis.
    Zhang T; Wei Y; Cui H; Tang X; Xu L; Hu Y; Tang Y; Liu H; Chen T; Li C; Wang J
    Psychiatry Res; 2023 Sep; 327():115385. PubMed ID: 37567111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Models of mild cognitive deficits in risk assessment in early psychosis.
    Zhang T; Cui H; Tang X; Xu L; Wei Y; Hu Y; Tang Y; Wang Z; Liu H; Chen T; Li C; Wang J
    Psychol Med; 2024 Jul; 54(9):2230-2241. PubMed ID: 38433595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel N100 area reliably captures aberrant sensory processing and is associated with neurocognition in early psychosis.
    Machiraju SN; Wyss J; Light G; Braff DL; Cadenhead KS
    Schizophr Res; 2024 Sep; 271():71-80. PubMed ID: 39013347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Untreated Prodromal Psychosis and Cognitive Impairments.
    Zhang T; Cui H; Wei Y; Tang X; Xu L; Hu Y; Tang Y; Liu H; Wang Z; Chen T; Li C; Wang J
    JAMA Netw Open; 2024 Jan; 7(1):e2353426. PubMed ID: 38277145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: a meta-analysis.
    De Herdt A; Wampers M; Vancampfort D; De Hert M; Vanhees L; Demunter H; Van Bouwel L; Brunner E; Probst M
    Schizophr Res; 2013 Sep; 149(1-3):48-55. PubMed ID: 23830855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal change in neurocognition and its relation to symptomatic and functional changes over 2years in individuals at clinical high-risk for psychosis.
    Shin YS; Kim SY; Lee TY; Hur JW; Shin NY; Kim SN; Shin MS; Kwon JS
    Schizophr Res; 2016 Jul; 174(1-3):50-57. PubMed ID: 27068568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting psychosis risk using a specific measure of cognitive control: a 12-month longitudinal study.
    Guo JY; Niendam TA; Auther AM; Carrión RE; Cornblatt BA; Ragland JD; Adelsheim S; Calkins R; Sale TG; Taylor SF; McFarlane WR; Carter CS
    Psychol Med; 2020 Oct; 50(13):2230-2239. PubMed ID: 31507256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.